OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
August 02, 2021
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
Types of delivery methods currently being explored to improve treatment for patients with retinal disorders.
July 26, 2021
Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.
Challenges associated with delivering therapies currently available to treat retinal disorders and methods being explored to improve drug delivery to patients.
July 21, 2021
Why investigators are considering AMD to be a disease spectrum rather than a single disease.
July 19, 2021
Drawbacks and challenges associated with the administration of anti-VEGF injections currently available to treat retinal diseases.
Dr Mariya Moosajee highlights therapies approved as well as under study to improve treatment for patients with inherited retinal disease.
July 15, 2021
Promoting Tie2 signaling activity may complement inhibition of VEGF in addressing pathology in disease states characterized by angiogenesis, vascular permeability, and inflammation.
July 13, 2021
Trial shows treatment has acceptable safety profile, may improve visual function.
July 12, 2021
A discussion regarding the roles of various treatments available for diabetic macular edema and considerations for selecting and sequencing therapy.